Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix Group reports a robust 16% revenue increase to $16.4 million in the first half of 2024, marking its seventh consecutive period of growth and a confident continuation of their profitable trajectory since 2021. The company’s BioRinse and dCELL segments show solid growth and operational efficiency, contributing to the promising financial performance. With a strong cash position, Tissue Regenix is optimistic about its ongoing business expansion and future stakeholder returns.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
